Bio-Rad Launches IncRNA Workflow, a RT-qPCR Workflow Optimized for Long Noncoding RNA Discovery and Validation
Toolkit Provides Streamlined, Cost-Effective Alternative to RNA-Seq
HERCULES, Calif. — March 8, 2018 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced the launch of IncRNA Workflow, a RT-qPCR workflow that is optimized for highly sensitive and specific quantification of long noncoding RNAs (lncRNAs) for gene expression analysis. The workflow provides a streamlined, cost-effective alternative to RNA-Seq for lncRNA discovery and validation.
Quantification of lncRNAs is particularly difficult due to low expression levels seen in some developmental contexts or with certain cell types. Furthermore, lncRNA primer design requires significant time and effort as targets are often positioned in complex genomic loci and can form secondary structures. PrimePCR lncRNA assay designs were developed in collaboration with transcriptome experts at BioGazelle using a design algorithm specifically built for long noncoding RNAs.
Bio-Rad’s lncRNA Workflow solves the most pressing challenges in lncRNA discovery and validation with its workflow that includes PrimePCR lncRNA Assays, Predesigned PrimePCR lncRNA Arrays, Custom PrimePCR lncRNA Arrays, and the novel iScript Explore One-Step RT and PreAmp Kit. The workflow offers all the tools necessary to go from experimental sample to lncRNA data analysis.
Researchers can use iScript Explore One-Step RT and PreAmp Kit to preamplify low-abundance lncRNAs, a critical step that expands the number of targets that can be assayed from limited sample material. This single kit allows researchers to perform genomic DNA digestion, reverse transcription and preamplification. Even difficult targets can become readily detectable with the included proprietary reaction booster technology.
For laboratories that find using RNA-Seq for lncRNA discovery is expensive and time-consuming, Bio-Rad’s 20 predesigned PrimePCR lncRNA Arrays cover the most active fields for lncRNA research, including cancer, immunology, stem cell biology, and more. The predesigned arrays are expertly curated to include a combination of frequently cited lncRNAs and novel lncRNAs identified through bioinformatic analysis to aid in target discovery. The plates can be paired with Bio-Rad’s new Preblended lncRNA PreAmp Assay Pools, which contain all assays necessary to preamplify targets on the corresponding predesigned array, thereby greatly reducing hands-on setup time.
The lncRNA workflow also offers solutions for researchers who have already identified lncRNAs they wish to study and who want to validate or expand their discovery work with a larger group of samples. Bio-Rad’s Custom PrimePCR lncRNA Arrays can be designed to include anywhere from 10 to 384 lncRNA and mRNA targets per array. When desired, researchers can also include self-designed individual assays in custom arrays.
The lncRNA workflow is fully compatible with Bio-Rad’s CFX Real-Time PCR Detection Systems with CFX Maestro Analysis Software, SsoAdvanced Supermixes, and plastic consumables.
Please visit www.bio-rad.com/lncRNAworkflow for more information about the lncRNA workflow.
Bio-Rad, PrimePCR, iScript, SsoAdvanced, and CFX Maestro are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The Company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The Company employs more than 8,350 people worldwide and had revenues exceeding $2 billion in 2016. For more information, please visit www.bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our development and launch of new products and our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “can,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, product quality and liability issues, our ability to compete effectively, and international legal and regulatory risks. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Report on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Bio-Rad Laboratories, Inc.
Jennifer Dennis, PhD